ChromaDex Corporation provided earnings guidance for the year 2022. Looking forward, for the full year, the Company expects high single digit revenue growth, driven by its global e-commerce business and growth with partners.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.73 USD | +0.74% |
|
-8.39% | +90.91% |
Jun. 13 | Chromadex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® | CI |
Jun. 07 | Sector Update: Health Care Stocks Higher Late Afternoon | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+90.91% | 207M | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- CDXC Stock
- News ChromaDex Corporation
- ChromaDex Corporation Provides Earnings Guidance for the Year 2022